What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Diabetes mellitus
- Type 2 diabetes
His main research concerns Internal medicine, Diabetes mellitus, Type 2 diabetes, Endocrinology and Randomized controlled trial.
His study in Internal medicine is interdisciplinary in nature, drawing from both Placebo, Type 2 Diabetes Mellitus and Cardiology.
His Diabetes mellitus research incorporates elements of Clinical trial, Kidney disease and Hazard ratio.
The Type 2 diabetes study combines topics in areas such as Smoking cessation, Renal function, Urology, Pharmaceutical industry and Disease.
Crossover study is closely connected to Gastroenterology in his research, which is encompassed under the umbrella topic of Endocrinology.
His Myocardial infarction research integrates issues from Stroke and Physical therapy.
His most cited work include:
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. (935 citations)
- The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. (577 citations)
- Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial (508 citations)
What are the main themes of his work throughout his whole career to date?
Lawrence A. Leiter mostly deals with Internal medicine, Diabetes mellitus, Type 2 diabetes, Endocrinology and Placebo.
He combines subjects such as Gastroenterology, Type 2 Diabetes Mellitus and Cardiology with his study of Internal medicine.
His research in the fields of Glycemic overlaps with other disciplines such as In patient.
His study looks at the relationship between Type 2 diabetes and topics such as Hypoglycemia, which overlap with Surgery.
His Endocrinology study frequently draws connections between adjacent fields such as Carbohydrate.
The various areas that Lawrence A. Leiter examines in his Placebo study include Adverse effect, Dapagliflozin and Hazard ratio.
He most often published in these fields:
- Internal medicine (86.57%)
- Diabetes mellitus (52.84%)
- Type 2 diabetes (43.88%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (86.57%)
- Type 2 diabetes (43.88%)
- Diabetes mellitus (52.84%)
In recent papers he was focusing on the following fields of study:
Lawrence A. Leiter focuses on Internal medicine, Type 2 diabetes, Diabetes mellitus, Placebo and In patient.
His Internal medicine research incorporates elements of Dapagliflozin and Cardiology.
His Type 2 diabetes research includes elements of Post-hoc analysis, Blood pressure and Hazard ratio.
His work on Type 2 Diabetes Mellitus as part of general Diabetes mellitus study is frequently linked to EMPA, therefore connecting diverse disciplines of science.
He has included themes like Dulaglutide, Familial hypercholesterolemia, Adverse effect and Confidence interval in his Placebo study.
His research in Myocardial infarction focuses on subjects like Stroke, which are connected to Meta-analysis.
Between 2018 and 2021, his most popular works were:
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. (935 citations)
- Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. (226 citations)
- Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. (209 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Diabetes mellitus
- Type 2 diabetes
His primary areas of study are Internal medicine, Diabetes mellitus, Randomized controlled trial, Type 2 Diabetes Mellitus and Placebo.
His Internal medicine research is multidisciplinary, relying on both Type 2 diabetes and Cardiology.
His Type 2 diabetes research incorporates themes from Stroke and Hazard ratio.
His Diabetes mellitus study integrates concerns from other disciplines, such as Heart failure and Kidney disease.
His Randomized controlled trial research focuses on Clinical trial and how it connects with Sotagliflozin.
His study in Placebo is interdisciplinary in nature, drawing from both Familial hypercholesterolemia, Clinical endpoint and Montreal Cognitive Assessment.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
